Long term outcome of Fanhdi in Haemophilia A patients in London

Trial Profile

Long term outcome of Fanhdi in Haemophilia A patients in London

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2016 Planned End Date changed from 28 Feb 2016 to 30 Jun 2016 as per United Kingdom Clinical Research Network record.
    • 13 Oct 2015 Planned End Date changed from 1 Sep 2015 to 28 Feb 2016 as per United Kingdom Clinical Research Network record.
    • 17 Sep 2015 Accrual to date is 143% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top